Ocugen Faces a Defining Week: Shareholder Vote and a $130M Bet on Three Gene Therapy Approvals

Ocugen shareholders vote on directors and audit amid 55% stock drop; pipeline nears BLA filings for three gene therapies with extended funding into 2028.

Ocugen’s shareholders are casting their ballots on Thursday in a virtual annual meeting that will test confidence in the boardroom while the company’s shares trade near their lows. The agenda includes the election of two directors, ratification of PwC as auditor, and approval of executive compensation — but the backdrop is a stock that has shed more than half its value since March.

The vote comes on the heels of a critical capital injection. In May, Ocugen raised $130 million in gross proceeds through convertible notes. After covering costs and retiring an existing loan, the company now expects its funding to last into 2028. That runway buys time for a pipeline that remains firmly on track for three Biologics License Applications within the next three years.

Pipeline Progress Accelerates

The lead program, OCU400, has completed enrollment of 140 patients in the liMeliGhT study — the largest pivotal gene therapy trial for retinitis pigmentosa, a condition tied to mutations in over 100 genes. Ocugen plans to begin a rolling BLA submission in the third quarter of 2026 and finish by mid-2027.

Right behind it is OCU410 for geographic atrophy. The Phase 2 ArMaDa study delivered a statistically significant 31% reduction in lesion growth at 12 months compared to the control group. The therapy is a first-in-class RORA-based gene therapy designed to target drusen, inflammation, oxidative stress, and complement activation simultaneously — a multi-pathway approach that goes beyond existing approved treatments.

A third program, OCU410ST for Stargardt disease, is nearing the close of enrollment in its pivotal Phase 2/3 study. Interim data are expected in the third quarter of 2026, with full results due in the second quarter of 2027. All three late-stage programs are marching toward BLA filings, and management insists the timeline is holding.

Market Punishes Progress

Despite the scientific momentum, Ocugen’s stock has tumbled. The shares now trade at EUR1.04, more than 55% below the March high of EUR2.35. Over the past 30 days, the stock has lost 18% and sits roughly 23% below its 50-day moving average. The relative strength index stands at 32.1, technically in oversold territory.

The latest trigger was the Q1 2026 earnings report. Ocugen posted a loss per share of minus $0.06, a penny worse than the minus $0.05 forecast. Revenue, however, came in at $1.53 million, tripling the consensus estimate of about $500,000. The stock still fell sharply in pre-market trading.

It’s a familiar pattern in pre-revenue biotech: the market punishes the bottom line while largely ignoring operational advances that don’t fit neatly into an earnings number. A similar dynamic played out in January, when a Phase 2 reading for OCU410 showed efficacy but the stock initially dropped nearly 15% before recovering after hours.

Regulatory Tailwinds Gain Strength

The broader regulatory environment is turning more favorable. Early in 2026, the FDA announced a more flexible approach to cell and gene therapy approvals, aiming to speed product development and better prepare BLA submissions. A concrete sign came when the agency cleared a gene therapy for genetic hearing loss just 61 days after its BLA filing — one of the fastest review cycles in modern FDA history.

That climate should benefit Ocugen, which has three late-stage programs — more than most peers — but the market currently values the entire company at around EUR374 million, a figure that barely reflects the pipeline’s potential.

A Concentrated Catalyst Window

The third quarter of 2026 will be the proving ground. Interim data for OCU410ST, the start of a Phase 3 study for OCU410, and the beginning of the rolling BLA submission for OCU400 all converge in the same period. Three potential catalysts in one quarter, while the stock sits in oversold territory with annualized volatility of roughly 72%.

Before that, Ocugen will present at a Las Vegas conference on June 13, where clinical data will again take center stage. For now, the shareholder vote offers a first test of whether the investor base believes the financing, the science, and the leadership are aligned to deliver on that promise.